Description
Fluticasone is an agonist at β2-adrenergic receptors that is clinically used to treat asthma and COPD; it exhibits anti-inflammatory, vasodilatory, anti-asthma, and anti-allergic activities. In airway epithelial cells, fluticasone increases expression of IκB kinase, preventing activation of NF-κB. In other in vitro models, fluticasone decreases lymphocyte activation, particularly mast cell activation, and decreases IL-6 levels. In animal models, fluticasone upregulates Smad7 and downregulates phospho-Smad2/3 and TGF-β1 levels, preventing eosinophilic inflammation and airway remodeling.
References
Kan-O K, Matsumoto K, Inoue H, et al. Corticosteroids plus long-acting β2-agonists prevent double-stranded RNA-induced upregulation of B7-H1 on airway epithelium. Int Arch Allergy Immunol. 2013;160(1):27-36. PMID: 22948082.
Mendes ES, Horvath G, Campos M, et al. Rapid corticosteroid effect on beta(2)-adrenergic airway and airway vascular reactivity in patients with mild asthma. J Allergy Clin Immunol. 2008 Mar;121(3):700-4. PMID: 18086493.
Lee SY, Kim JS, Lee JM, et al. Inhaled corticosteroid prevents the thickening of airway smooth muscle in murine model of chronic asthma. Pulm Pharmacol Ther. 2008;21(1):14-9. PMID: 17142077.
Edwards MR, Haas J, Panettieri RA Jr, et al. Corticosteroids and beta2 agonists differentially regulate rhinovirus-induced interleukin-6 via distinct Cis-acting elements. J Biol Chem. 2007 May 25;282(21):15366-75. PMID: 17395587.
Booth H, Richmond I, Ward C, et al. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med. 1995 Jul;152(1):45-52. PMID: 7599861.
